Articles from SV Health Investors

SV Health Investors (“SVHI”), a healthcare and life sciences focused private investment firm, announced today the acquisition of EpiVax, Inc. Headquartered in Providence, RI, EpiVax is a leading bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech companies. EpiVax has been a pioneer in pre-clinical drug development for over 25 years, serving as a trusted scientific advisor to life sciences clients. EpiVax represents a new platform investment for SV Health Investors, building on SVHI’s deep experience in outsourced pharma services.

SV Health Investors (“SV”), a leading healthcare-focused private equity firm, is pleased to announce the promotion of A.J. Rossi to Partner on the firm’s Growth-Buyout team. In this new role, A.J. will continue to lead investments and manage the SV portfolio, while helping to drive the firm’s growth initiatives across the healthcare sector.